Dongsian cardiovascular system 1 new drugs approved clinically this year has declared 6 new drugs 1 class

November 30, the latest update of CDE, Dongsian 1 new drug HEC95468 was approved for the first time clinically, for pulmonary hypertension (PAH), chronic thromboembolism pulmonary hypertension (CTEPH).
pulmonary hypertension (pulmonary arterial hypertension, PAH) is a type of malignant pulmonary vascular disease characterized by pulmonary pressure, which usually leads to right heart failure or even death.
is known as "cancer in cardiovascular disease" because of its difficulty in early diagnosis and high mortality.
, patient survival has improved with the launch of targeted drugs.
currently, targeted drugs for PAH mainly include endotide-specific antagonists, type 5 phosphate dipesterase inhibitors, prostatin IP-subjectors, synthetic procetatin analogosomes, bird glycoside cyclase astrogens.
, however, heC95468 of East Sunshine has not yet been queried for target disclosure, and its mechanism of action and preclinical data have not been known.
2020, Dongsian has declared 20 clinical trials of New Class 1 drugs involving six new drugs, including esinone, nicotoxine, HEC89736PTSA.0.5H2O, HEC122505MsOH, HEC95468, and HEC73077.
, Yvonne, Ningertinist non-first declared clinical, HEC89736PTSA.0.5H2O has been approved clinical, HEC122505MsOH has started Phase I clinical.
is a new class 1 drug developed by Dongsian autonomously for idyllytic pulmonary fibrosis.
the drug was first approved for clinical use on March 22, 2017, and certified as an FDA orphan drug on August 10, 2017.
, the Insight database shows that the drug was completed in November 2017 and May 2020, respectively, when two Phase I clinical trials were launched in the country.
is a multi-target tyrosine kinase inhibitor.
Insight database shows that Dongshe has launched clinical trials for its use in the treatment of renal cell carcinoma, advanced EGFR mutation/metastatic NSCLC, FLT3 mutation acute myeloid leukemia, stomach cancer and many other indications.
from: Insight Database () HEC89736PTSA.0.5H2O is a targeted PI3K anti-tumor new drug that has not yet started clinically; HEC122505MsOH Phase I clinically initiated for Parkinson's disease; and fibrosis new drug HEC73077 is still in clinical applications.
。